Sujet(s)
Sténose aortique , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/tendances , Remplacement valvulaire aortique par cathéter/méthodes , Femelle , Sténose aortique/chirurgie , Résultat thérapeutique , Facteurs sexuels , Mâle , Sujet âgéRÉSUMÉ
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has established itself as the preferential strategy to approach severe aortic stenosis. Information on procedural improvements and nationwide results obtained with the technique throughout the past decade are unknown. OBJECTIVES: To assess the temporal variation of the demographic profile, procedural characteristics, and in-hospital outcomes of patients undergoing TAVI procedures at the Rede D'Or São Luiz. METHODS: Observational registry comprising 29 national institutions, comparing the characteristics of the TAVI procedures performed from 2012 to 2017 (Group 1) to those performed from 2018 to 2023 (Group 2). The statistical significance level adopted was p < 0.05. RESULTS: This study assessed 661 patients, 95 in Group 1 and 566 in Group 2, with a mean age of 81.1 years. Group 1 patients had a higher prevalence of New York Heart Association functional class III or IV and STS risk score > 8%. In addition, they more often underwent general anesthesia, transesophageal echocardiographic monitoring, and access through femoral dissection. Group 2 patients had a higher success rate of the TAVI procedure (95.4% versus 89.5%; p = 0.018), lower mortality (3.9% versus 11.6%; p = 0.004), and less often needed permanent pacemaker implantation (8.5% versus 17.9%; p = 0.008). CONCLUSIONS: The 10-year temporal trends analysis of the TAVIDOR Registry shows a reduction in patients' clinical complexity over time. Furthermore, the advance to minimalistic implantation techniques, added to the technological evolution of the devices, may have contributed to the favorable outcomes observed among those whose implantation occurred in the last 5 years studied.
FUNDAMENTO: O implante percutâneo de bioprótese valvar aórtica (TAVI) consolidou-se como opção terapêutica da estenose aórtica de grau importante. Dados sobre as características evolutivas dos procedimentos e dos resultados obtidos com a técnica ao longo da última década, em escala nacional, são desconhecidos. OBJETIVOS: Analisar a tendência temporal referente ao perfil demográfico, características dos procedimentos e desfechos hospitalares de pacientes submetidos a TAVI na Rede D'Or São Luiz. MÉTODOS: Registro observacional envolvendo 29 instituições nacionais. Comparou-se características dos procedimentos realizados de 2012 a 2017 (Grupo 1) e de 2018 a 2023 (Grupo 2). Foram considerados significantes os resultados com valor de p < 0,05. RESULTADOS: Foram analisados 661 casos, 95 pertencentes ao Grupo 1 e 566 ao Grupo 2. A média de idade foi 81,1 anos. Observou-se no Grupo 1 maior prevalência de pacientes em classe funcional III ou IV e escore de risco > 8%. Foi mais frequente o emprego de anestesia geral, monitorização ecocardiográfica transesofágica e via de acesso por dissecção. Maior taxa de sucesso do procedimento (95,4% versus 89,5%; p = 0,018) foi aferida em implantes efetivados a partir de 2018, assim como menor mortalidade (3,9% versus 11,6%; p = 0,004) e necessidade de marcapasso definitivo (8,5% versus 17,9%; p = 0,008). CONCLUSÕES: A análise temporal de 10 anos do Registro TAVIDOR demonstra uma queda na complexidade clínica dos pacientes. Além disso, o avanço para técnicas de implante minimalistas, somadas à evolução tecnológica dos dispositivos, podem ter contribuído para desfechos favoráveis dentre aqueles cujo implante ocorreu no último quinquênio.
Sujet(s)
Sténose aortique , Enregistrements , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/tendances , Mâle , Femelle , Sujet âgé de 80 ans ou plus , Sténose aortique/chirurgie , Sujet âgé , Résultat thérapeutique , Facteurs temps , Facteurs de risque , Brésil/épidémiologie , Mortalité hospitalièreRÉSUMÉ
BACKGROUND: Transcatheter aortic valve replacement has become an accepted alternative to surgical aortic valve replacement. We examined the trends and predictors in inflation-adjusted costs of transcatheter aortic valve replacement and surgical aortic valve replacement. METHODS: National Inpatient Sample identified patients who underwent aortic valve replacement for severe aortic stenosis by International Classification of Diseases, Ninth and Tenth Revisions, codes. Hospitalization costs were inflation-adjusted using the Federal Reserve's consumer price index to reflect current valuation. Outcomes of interest were unadjusted trend in annual cost for each procedure and predictors of in-patient cost. Generalized linear models with a log link function identified predictors of adjusted costs. Interaction terms determined where cost predictors were different by operation type. RESULTS: Between 2011 and 2019, the mean annual inflation-adjusted cost of surgical aortic valve replacement increased from $62,853 to $63,743, in contrast to decreasing cost of transcatheter aortic valve replacement from $64,913 to $56,042 ($1,854 per year; P = .004). Significant independent predictors of patient-level cost included operation type (transcatheter aortic valve replacement associated with $9,625 increase; P < .001), incidence of in-hospital mortality ($28,836 increase; P < .001), elective status ($2,410 decrease; P < .001), Elixhauser Index ($995 increase; P < .001), and postoperative length of stay ($2,014 per day increase; P < .001). Compared to discharges with Medicare, discharges with private insurance and Medicaid paid $736 less (P = .004) and $1,863 less (P = .01), respectively. Increasing hospital volume was a significant predictor of decreasing patient level cost (P < .001). CONCLUSION: Annual cost of transcatheter aortic valve replacement has decreased significantly and has been a more cost-effective modality compared to surgical aortic valve replacement since 2017. Predictors of patient-level costs allow for mindful preparation of healthcare systems for aortic valve replacement.
Sujet(s)
Sténose aortique , Implantation de valve prothétique cardiaque , Remplacement valvulaire aortique par cathéter , Humains , Femelle , Mâle , Remplacement valvulaire aortique par cathéter/économie , Remplacement valvulaire aortique par cathéter/statistiques et données numériques , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , États-Unis , Sténose aortique/chirurgie , Sténose aortique/économie , Sujet âgé de 80 ans ou plus , Implantation de valve prothétique cardiaque/économie , Implantation de valve prothétique cardiaque/tendances , Implantation de valve prothétique cardiaque/méthodes , Implantation de valve prothétique cardiaque/statistiques et données numériques , Coûts hospitaliers/statistiques et données numériques , Coûts hospitaliers/tendances , Valve aortique/chirurgie , Études rétrospectives , Inflation économiqueRÉSUMÉ
BACKGROUND: Transcatheter (TAVR) has supplanted surgical (SAVR) aortic valve replacement (AVR). AIM: To evaluate whether adoption of this technology has varied according to centre volume at the nationwide level. METHODS: From an administrative hospital-discharge database, we collected data on all AVRs performed in France between 2007 and 2019. Centres were divided into terciles based on the annual number of SAVRs performed in 2007-2009 ("before TAVR era"). RESULTS: A total of 192,773 AVRs (134,662 SAVRs and 58,111 TAVRs) were performed in 47 centres. The annual number of AVRs and TAVRs increased significantly and linearly in low-volume (<152 SAVRs/year; median 106, interquartile range [IQR] 75-129), middle-volume (152-219 SAVRs/year; median 197, IQR 172-212) and high-volume (>219 SAVRs/year; median 303, IQR 268-513) terciles, but to a greater degree in the latter (+14, +16 and +24 AVRs/centre/year and +16, +19 and +31 TAVRs/centre/year, respectively; PANCOVA<0.001). Charlson Comorbidity Index and in-hospital death rates declined from 2010 to 2019 in all terciles (all Ptrend<0.05). In 2017-2019, after adjusting for age, sex and Charlson Comorbidity Index, there was a trend toward lower death rates in the high-volume tercile (P=0.06) for SAVR, whereas death rates were similar for TAVR irrespective of tercile (P=0.27). Similar results were obtained when terciles were defined based on number of interventions performed in the last instead of the first 3years. Importantly, even centres in the lowest-volume tercile performed a relatively high number of interventions (150 TAVRs/year/centre). CONCLUSIONS: In a centralized public healthcare system, the total number of AVRs increased linearly between 2007 and 2019, mostly due to an increase in TAVR, irrespective of centre volume. Progressive declines in patient risk profiles and death rates were observed in all terciles; in 2017-2019 death rates were similar in all terciles, although lower in high-volume centres for SAVR.
Sujet(s)
Sténose aortique , Valve aortique , Bases de données factuelles , Implantation de valve prothétique cardiaque , Hôpitaux à haut volume d'activité , Hôpitaux à faible volume d'activité , Remplacement valvulaire aortique par cathéter , Humains , Sténose aortique/chirurgie , Sténose aortique/mortalité , Sténose aortique/physiopathologie , Sténose aortique/imagerie diagnostique , France/épidémiologie , Hôpitaux à haut volume d'activité/tendances , Remplacement valvulaire aortique par cathéter/tendances , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/effets indésirables , Femelle , Hôpitaux à faible volume d'activité/tendances , Mâle , Sujet âgé , Résultat thérapeutique , Facteurs temps , Valve aortique/chirurgie , Valve aortique/physiopathologie , Facteurs de risque , Sujet âgé de 80 ans ou plus , Implantation de valve prothétique cardiaque/mortalité , Implantation de valve prothétique cardiaque/effets indésirables , Implantation de valve prothétique cardiaque/tendances , Implantation de valve prothétique cardiaque/instrumentation , Types de pratiques des médecins/tendances , Appréciation des risques , Études rétrospectives , Complications postopératoires/épidémiologie , Complications postopératoires/mortalité , Diffusion des innovationsRÉSUMÉ
BACKGROUND: Next-day discharge (NDD) outcomes following uncomplicated self-expanding transcatheter aortic valve replacement have not been studied. Here, we compare readmission rates and clinical outcomes in NDD versus non-NDD transcatheter aortic valve replacement with Evolut. METHODS AND RESULTS: Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry patients (n=29 597) undergoing elective transcatheter aortic valve replacement with self-expanding supra-annular valves (Evolut R, PRO, and PRO+) from July 2019 to June 2021 were stratified by postprocedure length of stay: ≤1 day (NDD) versus >1 day (non-NDD). Propensity score matching was used to compare risk adjusted 30-day readmission rates and 1-year outcomes in NDD versus non-NDD, and multivariable regression to determine predictors of NDD and readmission. Between the first and last calendar quarter, the rate of NDD increased from 45.4% to 62.1% and median length of stay decreased from 2 days to 1. Propensity score matching produced relatively well-matched NDD and non-NDD cohorts (n=10 549 each). After matching, NDD was associated with lower 30-day readmission rates (6.3% versus 8.4%; P<0.001) and 1-year adverse outcomes (death, 7.0% versus 9.3%; life threatening/major bleeding, 1.6% versus 3.4%; new permanent pacemaker implantation/implantable cardioverter-defibrillator, 3.6 versus 11.0%; [all P<0.001]). Predictors of NDD included non-Hispanic ethnicity, preexisting permanent pacemaker implantation/implantable cardioverter-defibrillator, and previous surgical aortic valve replacement. CONCLUSIONS: Most patients undergoing uncomplicated self-expanding Evolut transcatheter aortic valve replacement are discharged the next day. This study found that NDD can be predicted from baseline patient characteristics and was associated with favorable 30-day and 1-year outcomes, including low rates of permanent pacemaker implantation and readmission.
Sujet(s)
Sténose aortique , Sortie du patient , Réadmission du patient , Score de propension , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/tendances , Réadmission du patient/statistiques et données numériques , Réadmission du patient/tendances , Mâle , Femelle , Sujet âgé de 80 ans ou plus , Sténose aortique/chirurgie , Sténose aortique/mortalité , Sujet âgé , Sortie du patient/tendances , Enregistrements , Durée du séjour/statistiques et données numériques , Durée du séjour/tendances , Facteurs temps , Prothèse valvulaire cardiaque , Complications postopératoires/épidémiologie , Résultat thérapeutique , États-Unis/épidémiologie , Facteurs de risque , Valve aortique/chirurgie , Études rétrospectives , Conception de prothèse , Appréciation des risquesRÉSUMÉ
OBJECTIVE: Management of patients with severe aortic stenosis (AS) may differ according to the patient sex. This study aimed to describe patterns of aortic valve replacement (AVR) for severe AS across Europe, including stratification by sex. METHODS: Procedure volume data for surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) for six years (2015-2020) were extracted from national databases for Austria, Czech Republic, Denmark, England, Finland, France, Germany, Norway, Poland, Spain, Sweden, and Switzerland and stratified by sex. Patients per million population (PPM) undergoing AVR per year were calculated using population estimates from Eurostat. RESULTS: Between 2015 and 2019, AVR procedures grew at an average annual rate of 3.9%. In 2020, the average total PPM undergoing AVR across all countries was 339, with 51% of procedures being TAVI and 49% SAVR. AVR PPM varied widely between countries, with the highest and lowest in Germany and Poland, respectively. The average total PPM was higher for men than women (423 vs. 258), but a higher proportion of women (62%) than men (44%) received TAVI. The proportion of TAVI among total AVR procedures increased with age, with an overall average of 96% of men and 98% of women aged ≥85 years receiving TAVI; however, adoption of TAVI varied by country. CONCLUSIONS: The analysis of temporal trends in the adoption of TAVI vs. SAVR across Europe showed significant variations. Despite the higher use of TAVI vs. SAVR in women, overall rates of AV intervention in women were lower compared to men.
Sujet(s)
Sténose aortique , Humains , Femelle , Mâle , Europe/épidémiologie , Sujet âgé , Sténose aortique/chirurgie , Sténose aortique/épidémiologie , Sujet âgé de 80 ans ou plus , Facteurs sexuels , Remplacement valvulaire aortique par cathéter/tendances , Remplacement valvulaire aortique par cathéter/statistiques et données numériques , Implantation de valve prothétique cardiaque/tendances , Implantation de valve prothétique cardiaque/statistiques et données numériques , Valve aortique/chirurgie , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Prior studies have reported decreased use of an invasive approach for acute myocardial infarction (AMI) in patients undergoing transcatheter aortic valve replacement (TAVR). OBJECTIVES: The aim of this study was to determine whether prior TAVR affects the use of subsequent coronary revascularization and outcomes of AMI in a contemporary national data set. METHODS: Consecutive TAVR patients from 2016 to 2022 were identified from the U.S. Vizient Clinical Data Base who were hospitalized after the index TAVR hospitalization with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). Patients with STEMI or NSTEMI with or without prior TAVR from the same time period were compared for the use of coronary angiography, revascularization, and in-hospital outcomes. Propensity score matching was used to account for imbalances in patient characteristics. RESULTS: Among 206,229 patients who underwent TAVR, the incidence of STEMI was 25 events per 100,000 person-years of follow-up, and that of NSTEMI was 229 events per 100,000 person-years. After propensity matching, the use of coronary revascularization was similar in the prior TAVR and no TAVR cohorts in both the STEMI (65.3% vs 63.9%; P = 0.81) and NSTEMI (41.4% vs 41.7%; P = 0.88) subgroups. Compared with patients without prior TAVR, in-hospital mortality was higher in the prior TAVR cohort in patients with STEMI (27.1% vs 16.7%; P = 0.03) and lower in those with NSTEMI (5.8% vs 8.2%; P = 0.02). CONCLUSIONS: In this large, national retrospective study, AMI events after TAVR were infrequent. There were no differences in the use of coronary revascularization for STEMI or NSTEMI in TAVR patients compared with the non-TAVR population. In-hospital mortality for STEMI is higher in TAVR patients compared with those without prior TAVR.
Sujet(s)
Sténose aortique , Bases de données factuelles , Mortalité hospitalière , Infarctus du myocarde sans sus-décalage du segment ST , Infarctus du myocarde avec sus-décalage du segment ST , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/tendances , Mâle , Femelle , États-Unis/épidémiologie , Résultat thérapeutique , Infarctus du myocarde sans sus-décalage du segment ST/mortalité , Infarctus du myocarde sans sus-décalage du segment ST/thérapie , Infarctus du myocarde sans sus-décalage du segment ST/imagerie diagnostique , Sujet âgé , Facteurs de risque , Facteurs temps , Sujet âgé de 80 ans ou plus , Appréciation des risques , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/imagerie diagnostique , Incidence , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Sténose aortique/mortalité , Sténose aortique/physiopathologie , Études rétrospectives , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/mortalité , Intervention coronarienne percutanée/tendancesRÉSUMÉ
BACKGROUND AND AIMS: Severe aortic stenosis (AS) is the guideline-based indication for aortic valve replacement (AVR), which has markedly increased with transcatheter approaches, suggesting possible increasing AS incidence. However, reported secular trends of AS incidence remain contradictory and lack quantitative Doppler echocardiographic ascertainment. METHODS: All adults residents in Olmsted County (MN, USA) diagnosed over 20 years (1997-2016) with incident severe AS (first diagnosis) based on quantitatively defined measures (aortic valve area ≤ 1â cm2, aortic valve area index ≤ 0.6â cm2/m2, mean gradient ≥ 40â mmHg, peak velocity ≥ 4â m/s, Doppler velocity index ≤ 0.25) were counted to define trends in incidence, presentation, treatment, and outcome. RESULTS: Incident severe AS was diagnosed in 1069 community residents. The incidence rate was 52.5 [49.4-55.8] per 100 000 patient-year, slightly higher in males vs. females and was almost unchanged after age and sex adjustment for the US population 53.8 [50.6-57.0] per 100 000 residents/year. Over 20 years, severe AS incidence remained stable (P = .2) but absolute burden of incident cases markedly increased (P = .0004) due to population growth. Incidence trend differed by sex, stable in men (incidence rate ratio 0.99, P = .7) but declining in women (incidence rate ratio 0.93, P = .02). Over the study, AS clinical characteristics remained remarkably stable and AVR performance grew and was more prompt (from 1.3 [0.1-3.3] years in 1997-2000 to 0.5 [0.2-2.1] years in 2013-16, P = .001) but undertreatment remained prominent (>40%). Early AVR was associated with survival benefit (adjusted hazard ratio 0.55 [0.42-0.71], P < .0001). Despite these improvements, overall mortality (3-month 8% and 3-year 36%), was swift, considerable and unabated (all P ≥ .4) throughout the study. CONCLUSIONS: Over 20 years, the population incidence of severe AS remained stable with increased absolute case burden related to population growth. Despite stable severe AS presentation, AVR performance grew notably, but while declining, undertreatment remained substantial and disease lethality did not yet decline. These population-based findings have important implications for improving AS management pathways.
Sujet(s)
Sténose aortique , Humains , Sténose aortique/épidémiologie , Mâle , Femelle , Incidence , Sujet âgé , Adulte d'âge moyen , Minnesota/épidémiologie , Sujet âgé de 80 ans ou plus , Remplacement valvulaire aortique par cathéter/tendances , Remplacement valvulaire aortique par cathéter/statistiques et données numériques , Échocardiographie-doppler , Implantation de valve prothétique cardiaque/tendances , Implantation de valve prothétique cardiaque/statistiques et données numériques , Indice de gravité de la maladie , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Recent trends, including survival beyond 30 days, in aortic valve replacement (AVR) following the expansion of indications for transcatheter aortic valve replacement (TAVR) are not well-understood. OBJECTIVES: The authors sought to characterize the trends in characteristics and outcomes of patients undergoing AVR. METHODS: The authors analyzed Medicare beneficiaries who underwent TAVR and SAVR in 2012 to 2019. They evaluated case volume, demographics, comorbidities, 1-year mortality, and discharge disposition. Cox proportional hazard models were used to assess the annual change in outcomes. RESULTS: Per 100,000 beneficiary-years, AVR increased from 107 to 156, TAVR increased from 19 to 101, whereas SAVR declined from 88 to 54. The median [interquartile range] age remained similar from 77 [71-83] years to 78 [72-84] years for overall AVR, decreased from 84 [79-88] years to 81 [75-86] years for TAVR, and decreased from 76 [71-81] years to 72 [68-77] years for SAVR. For all AVR patients, the prevalence of comorbidities remained relatively stable. The 1-year mortality for all AVR decreased from 11.9% to 9.4%. Annual change in the adjusted odds of 1-year mortality was 0.93 (95% CI: 0.92-0.94) for TAVR and 0.98 (95% CI: 0.97-0.99) for SAVR, and 0.94 (95% CI: 0.93-0.95) for all AVR. Patients discharged to home after AVR increased from 24.2% to 54.7%, primarily driven by increasing home discharge after TAVR. CONCLUSIONS: The advent of TAVR has led to about a 60% increase in overall AVR in older adults. Improving outcomes in AVR as a whole following the advent of TAVR with increased access is a reassuring trend.
Sujet(s)
Sténose aortique/chirurgie , Valve aortique/chirurgie , Medicare (USA)/statistiques et données numériques , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/épidémiologie , Femelle , Études de suivi , Mortalité hospitalière/tendances , Humains , Mâle , Études rétrospectives , Facteurs de risque , Taux de survie/tendances , Facteurs temps , États-Unis/épidémiologieRÉSUMÉ
Background Patients with symptomatic severe aortic stenosis (ssAS) have a high mortality risk and compromised quality of life. Surgical/transcatheter aortic valve replacement (AVR) is a Class I recommendation, but it is unclear if this recommendation is uniformly applied. We determined the impact of managing cardiologists on the likelihood of ssAS treatment. Methods and Results Using natural language processing of Optum electronic health records, we identified 26 438 patients with newly diagnosed ssAS (2011-2016). Multilevel, multivariable Fine-Gray competing risk models clustered by cardiologists were used to determine the impact of cardiologists on the likelihood of 1-year AVR treatment. Within 1 year of diagnosis, 35.6% of patients with ssAS received an AVR; however, rates varied widely among managing cardiologists (0%, lowest quartile; 100%, highest quartile [median, 29.6%; 25th-75th percentiles, 13.3%-47.0%]). The odds of receiving AVR varied >2-fold depending on the cardiologist (median odds ratio for AVR, 2.25; 95% CI, 2.14-2.36). Compared with patients with ssAS of cardiologists with the highest treatment rates, those treated by cardiologists with the lowest AVR rates experienced significantly higher 1-year mortality (lowest quartile, adjusted hazard ratio, 1.22, 95% CI, 1.13-1.33). Conclusions Overall AVR rates for ssAS were low, highlighting a potential challenge for ssAS management in the United States. Cardiologist AVR use varied substantially; patients treated by cardiologists with lower AVR rates had higher mortality rates than those treated by cardiologists with higher AVR rates.
Sujet(s)
Sténose aortique/chirurgie , Cardiologues/tendances , Implantation de valve prothétique cardiaque/tendances , Évaluation des résultats et des processus en soins de santé/tendances , Types de pratiques des médecins/tendances , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/imagerie diagnostique , Sténose aortique/mortalité , Sténose aortique/physiopathologie , Prise de décision clinique , Dossiers médicaux électroniques , Femelle , Implantation de valve prothétique cardiaque/effets indésirables , Implantation de valve prothétique cardiaque/mortalité , Humains , Mâle , Adulte d'âge moyen , Traitement du langage naturel , Études rétrospectives , Appréciation des risques , Facteurs de risque , Indice de gravité de la maladie , Facteurs temps , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/mortalité , Résultat thérapeutiqueRÉSUMÉ
Background Racial and ethnic inequities exist in surgical aortic valve replacement for aortic stenosis (AS), and early studies have suggested similar inequities in transcatheter aortic valve replacement. Methods and Results We performed a retrospective analysis of the Maryland Health Services Cost Review Commission inpatient data set from 2016 to 2018. Black patients had half the incidence of any inpatient AS diagnosis compared with White patients (incidence rate ratio [IRR], 0.50; 95% CI, 0.48-0.52; P<0.001) and Hispanic patients had one fourth the incidence compared with White patients (IRR, 0.25; 95% CI, 0.22-0.29; P<0.001). Conversely, the incidence of any inpatient mitral regurgitation diagnosis did not differ between White and Black patients (IRR, 1.00; 95% CI, 0.97-1.03; P=0.97) but was significantly lower in Hispanic compared with White patients (IRR, 0.36; 95% CI, 0.33-0.40; P<0.001). After multivariable adjustment, Black race was associated with a lower incidence of surgical aortic valve replacement (IRR, 0.67; 95% CI, 0.55-0.82 P<0.001 relative to White race) and transcatheter aortic valve replacement (IRR, 0.77; 95% CI, 0.65-0.90; P=0.002) among those with any inpatient diagnosis of AS. Hispanic patients had a similar rate of surgical aortic valve replacement and transcatheter aortic valve replacement compared with White patients. Conclusions Hospitalization with any diagnosis of AS is less common in Black and Hispanic patients than in White patients. In hospitalized patients with AS, Black race is associated with a lower incidence of both surgical aortic valve replacement and transcatheter aortic valve replacement compared with White patients, whereas Hispanic patients have a similar incidence of both. The reasons for these inequities are likely multifactorial.
Sujet(s)
Sténose aortique/ethnologie , Sténose aortique/chirurgie , /statistiques et données numériques , Hispanique ou Latino/statistiques et données numériques , Remplacement valvulaire aortique par cathéter/statistiques et données numériques , /statistiques et données numériques , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/mortalité , Cause de décès , Femelle , Équité en santé , Hospitalisation , Humains , Incidence , Mâle , Maryland/épidémiologie , Adulte d'âge moyen , Études rétrospectives , Facteurs de risque , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/tendancesRÉSUMÉ
Background The multidisciplinary Heart Team (HT) is recommended for management decisions for transcatheter aortic valve replacement (TAVR) candidates, and during TAVR procedures. Empiric evidence to support these recommendations is limited. We aimed to explore temporal trends, drivers, and outcomes associated with HT utilization. Methods and Results TAVR candidates were identified in Ontario, Canada, from April 1, 2012 to March 31, 2019. The HT was defined as having a billing code for both a cardiologist and cardiac surgeon during the referral period. The procedural team was defined as a billing code during the TAVR procedure. Hierarchical logistical models were used to determine the drivers of HT. Median odds ratios were calculated to quantify the degree of variation among hospitals. Of 10 412 patients referred for TAVR consideration, 5489 (52.7%) patients underwent a HT during the referral period, with substantial range between hospitals (median odds ratio of 1.78). Utilization of a HT for TAVR referrals declined from 69.9% to 41.1% over the years of the study. Patient characteristics such as older age, frailty and dementia, and hospital characteristics including TAVR program size, were found associated with lower HT utilization. In TAVR procedures, the procedural team included both cardiologists and cardiac surgeons in 94.9% of cases, with minimal variation over time or between hospitals. Conclusions There has been substantial decline in HT utilization for TAVR candidates over time. In addition, maturity of TAVR programs was associated with lower HT utilization.
Sujet(s)
Sténose aortique/chirurgie , Cardiologues/tendances , Équipe soignante/tendances , Types de pratiques des médecins/tendances , Chirurgiens/tendances , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Femelle , Humains , Mâle , Ontario , Évaluation de programme , Orientation vers un spécialiste/tendances , Études rétrospectives , Appréciation des risques , Facteurs de risque , Facteurs temps , Remplacement valvulaire aortique par cathéter/effets indésirables , Résultat thérapeutiqueSujet(s)
Sténose aortique/chirurgie , Valve aortique/chirurgie , COVID-19/épidémiologie , Prothèse valvulaire cardiaque , Remplacement valvulaire aortique par cathéter/tendances , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/épidémiologie , Comorbidité , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulteRÉSUMÉ
Background Transcatheter aortic valve replacement (TAVR) has transformed the management of aortic valve stenosis. However, little national data are available characterizing the geographic and demographic dispersion of this disruptive technology relative to surgical aortic valve replacement (SAVR). Methods and Results In this US claims-based study, we analyzed a 100% sample of fee-for-service Medicare beneficiaries from 2012 to 2017 and examined national rates of TAVR versus SAVR. Procedure rates were compared across years as a function of age, sex, race, and geography for TAVR and SAVR beneficiaries. There was significant growth in TAVR from 15.4 beneficiaries/100 000 enrollees in 2012 to 90.6 in 2017 (P<0.001). SAVR rates declined from 92.8 beneficiaries/100 000 enrollees in 2012 to 63.5 in 2017 (P<0.001). The growth of TAVR varied as a function of age (P<0.0001). While TAVR was the dominant strategy among beneficiaries ≥85 and 75 to 84 years old, SAVR was more common among beneficiaries 65 to 74 years old. TAVR was also used more frequently than SAVR among women (P<0.001). While TAVR increased among all races, it was less commonly used among non-White beneficiaries (P<0.001). Contemporary use of TAVR relative to SAVR varied significantly by geographic location, with a TAVR:SAVR ratio in 2017 of 1.24 in the Midwest and 1.68 in the Northeast (P<0.001). Conclusions In 2017, the number of Medicare beneficiaries receiving TAVR exceeded SAVR for the first time in the United States. There is significant variation, however, in the geographic expansion of TAVR and in patient demographics relative to SAVR.
Sujet(s)
Sténose aortique/chirurgie , Disparités d'accès aux soins/tendances , Types de pratiques des médecins/tendances , Chirurgiens/tendances , Remplacement valvulaire aortique par cathéter/tendances , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/imagerie diagnostique , Sténose aortique/ethnologie , Bases de données factuelles , Femelle , Humains , Mâle , Medicare (USA)/tendances , Facteurs raciaux , Facteurs sexuels , Facteurs temps , États-Unis/épidémiologieRÉSUMÉ
BACKGROUND: In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year. OBJECTIVES: This study determined both clinical and echocardiographic outcomes between 1 and 2 years in the PARTNER 3 trial. METHODS: This study randomly assigned 1,000 patients (1:1) to transfemoral TAVR with the SAPIEN 3 valve versus surgery (mean Society of Thoracic Surgeons score: 1.9%; mean age: 73 years) with clinical and echocardiography follow-up at 30 days and at 1 and 2 years. This study assessed 2-year rates of the primary endpoint and several secondary endpoints (clinical, echocardiography, and quality-of-life measures) in this as-treated analysis. RESULTS: Primary endpoint follow-up at 2 years was available in 96.5% of patients. The 2-year primary endpoint was significantly reduced after TAVR versus surgery (11.5% vs. 17.4%; hazard ratio: 0.63; 95% confidence interval: 0.45 to 0.88; p = 0.007). Differences in death and stroke favoring TAVR at 1 year were not statistically significant at 2 years (death: TAVR 2.4% vs. surgery 3.2%; p = 0.47; stroke: TAVR 2.4% vs. surgery 3.6%; p = 0.28). Valve thrombosis at 2 years was increased after TAVR (2.6%; 13 events) compared with surgery (0.7%; 3 events; p = 0.02). Disease-specific health status continued to be better after TAVR versus surgery through 2 years. Echocardiographic findings, including hemodynamic valve deterioration and bioprosthetic valve failure, were similar for TAVR and surgery at 2 years. CONCLUSIONS: At 2 years, the primary endpoint remained significantly lower with TAVR versus surgery, but initial differences in death and stroke favoring TAVR were diminished and patients who underwent TAVR had increased valve thrombosis. (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [PARTNER 3]; NCT02675114).
Sujet(s)
Sténose aortique/mortalité , Sténose aortique/chirurgie , Complications postopératoires/mortalité , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/imagerie diagnostique , Femelle , Études de suivi , Humains , Mâle , Complications postopératoires/imagerie diagnostique , Facteurs de risque , Taux de survie/tendances , Facteurs temps , Résultat thérapeutiqueSujet(s)
Sténose aortique/chirurgie , Mortalité hospitalière , Médiastin , Complications postopératoires/épidémiologie , Radiothérapie , Remplacement valvulaire aortique par cathéter/tendances , Atteinte rénale aigüe/épidémiologie , Répartition par âge , Sujet âgé , Sujet âgé de 80 ans ou plus , Tumeurs du sein/radiothérapie , Femelle , Maladie de Hodgkin/radiothérapie , Humains , Tumeurs du poumon/radiothérapie , Mâle , Tumeurs du médiastin/radiothérapie , Odds ratio , Sortie du patient/statistiques et données numériques , Hémorragie postopératoire/épidémiologie , Score de propension , Répartition par sexe , Choc cardiogénique/épidémiologie , Établissements de soins qualifiésRÉSUMÉ
AIMS: Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) are established options to treat aortic valve stenosis. We present the outcome of the complete cohort of all patients undergoing SAVR or TAVI in Germany during the calendar year 2019. METHODS AND RESULTS: Data concerning all isolated aortic valve procedures performed in Germany in 2019 were retrieved from the mandatory nationwide quality control program: 22,973 transvascular (TV)-TAVI procedures, 7905 isolated SAVR (iSAVR), and 1413 transapical (TA)-TAVI. Data was complete in 99.9% (n = 32,156). In-hospital mortality after TV-TAVI (2.3%) was significantly lower when compared with iSAVR (2.8%, p = 0.007) or TA-TAVI (6.3%; p < 0.001). Expected mortality was calculated with a new version of the German Aortic valve score (AKL Score) based on the data of either catheter-based (AKL-CATH) or surgical (AKL-CHIR) aortic valve replacements in Germany in 2018. TV-TAVI and iSAVR both showed lower observed mortality in 2019 than expected based on their respective performance in 2018, yielding an observed/expected (O/E) mortality ratio < 1. This was particularly apparent for patients at low risk. After exclusion of emergency procedures, in-hospital mortality after TV-TAVI (2.1%) and after iSAVR (2.1%) was identical, even though patients undergoing TV-TAVI showed a considerably higher perioperative risk profile. CONCLUSION: After excluding emergency procedures, in-hospital mortality of TV-TAVI and iSAVR in 2019 in Germany was identical. In 2019, TV-TAVI and iSAVR both show lower matched mortality ratios compared with 2018, which suggests technical improvements of both therapies.
Sujet(s)
Sténose aortique/chirurgie , Valve aortique/chirurgie , Remplacement valvulaire aortique par cathéter/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/épidémiologie , Femelle , Études de suivi , Allemagne/épidémiologie , Humains , Incidence , Mâle , Études rétrospectives , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Patterns of diffusion of TAVR in the United States (U.S.) and its relation to racial disparities in TAVR utilization remain unknown. METHODS: We identified TAVR hospitals in the continental U.S. from 2012-2017 using Medicare database and mapped them to Hospital Referral Regions (HRR). We calculated driving distance from each residential ZIP code to the nearest TAVR hospital and calculated the proportion of the U.S. population, in general and by race, that lived <100 miles driving distance from the nearest TAVR center. Using a discrete time hazard logistic regression model, we examined the association of hospital and HRR variables with the opening of a TAVR program. RESULTS: The number of TAVR hospitals increased from 230 in 2012 to 540 in 2017. The proportion of the U.S. population living <100 miles from nearest TAVR hospital increased from 89.3% in 2012 to 94.5% in 2017. Geographic access improved for all racial and ethnic subgroups: Whites (84.1%-93.6%), Blacks (90.0%- 97.4%), and Hispanics (84.9%-93.7%). Within a HRR, the odds of opening a new TAVR program were higher among teaching hospitals (OR 1.48, 95% CI 1.16-1.88) and hospital bed size (OR 1.44, 95% CI 1.37-1.52). Market-level factors associated with new TAVR programs were proportion of Black (per 1%, OR 0.78, 95% CI 0.69-0.89) and Hispanic (per 1%, OR 0.82, 95% CI 0.75-0.90) residents, the proportion of hospitals within the HRR that already had a TAVR program (per 10%, OR 1.07, 95% CI 1.03-1.11), P <.01 for all. CONCLUSION: The expansion of TAVR programs in the U.S. has been accompanied by an increase in geographic coverage for all racial subgroups. Further study is needed to determine reasons for TAVR underutilization in Blacks and Hispanics.
Sujet(s)
Établissements de cardiologie , Accessibilité des services de santé , Remplacement valvulaire aortique par cathéter , Humains , /statistiques et données numériques , Établissements de cardiologie/statistiques et données numériques , Établissements de cardiologie/tendances , Accessibilité des services de santé/statistiques et données numériques , Accessibilité des services de santé/tendances , Hispanique ou Latino/statistiques et données numériques , Capacité hospitalière/statistiques et données numériques , Hôpitaux d'enseignement/statistiques et données numériques , Hôpitaux d'enseignement/tendances , Modèles logistiques , Medicare (USA)/statistiques et données numériques , Mise au point de programmes/statistiques et données numériques , Orientation vers un spécialiste/statistiques et données numériques , Remplacement valvulaire aortique par cathéter/statistiques et données numériques , Remplacement valvulaire aortique par cathéter/tendances , États-Unis/ethnologie , BlancSujet(s)
Endocardite/imagerie diagnostique , Fluorodésoxyglucose F18/usage thérapeutique , Tomographie par émission de positons couplée à la tomodensitométrie/méthodes , Remplacement valvulaire aortique par cathéter/méthodes , Endocardite/chirurgie , Humains , Tomographie par émission de positons couplée à la tomodensitométrie/normes , Tomographie par émission de positons couplée à la tomodensitométrie/tendances , Remplacement valvulaire aortique par cathéter/normes , Remplacement valvulaire aortique par cathéter/tendancesRÉSUMÉ
Transcatheter aortic valve replacement (TAVR) has evolved toward a minimalist approach, resulting in shorter hospital stays. Real-world trends of next-day discharge (NDD) TAVR are unknown. This study aimed to evaluate underlying trends and readmissions of NDD TAVR. METHODS: This study was derived from the Nationwide Readmissions Database from 2012 to 2016. International Classification of Diseases, Ninth and Tenth Revisions, codes were used to identify patients. Any discharge within 1â¯day of admission was identified as NDD. NDD TAVR trends over the years were analyzed, and any admissions within 30â¯days were considered readmissions. A hierarchical logistic regression model was used to identify predictors of readmission. RESULTS: Of 49,742 TAVR procedures, 3,104 were NDD. The percentage of NDD TAVR increased from 1.5% (46/3,051) in 2012 to 12.2% (2,393/19,613) in 2016. However, the 30-day readmission rate remained the same over the years (8.6%). The patients' mean age was 80.3⯱â¯8.4â¯years. Major readmission causes were heart-failure exacerbation (16%), infections (9%), and procedural complications (8%). In 2016, there were significantly higher late conduction disorder and gastrointestinal bleeding readmission rates than in 2012-2015. Significant predictors of readmission were anemia, baseline conduction disease, cardiac arrhythmias, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, neoplastic disorders, and discharge to facility. CONCLUSIONS: The percentage of NDD TAVR increased over the years; however, readmission rates remained the same, with a higher rate of conduction abnormality-related hospitalizations in 2016. Careful discharge planning that includes identification of baseline factors that predict readmission and knowledge of etiologies may further prevent 30-day readmissions.